Table 3. Best response, PFS, OS of individual subtypes on pazopanib.
| Subtype (Total n = 33) | Best response | PFS (months) on data cut-off date | Status/OS (months) on data cut-off date |
|---|---|---|---|
|
ASPS (n = 2) Patient 1 Patient 2 |
PR SD |
7.8 15 |
Alive (24) Alive (17) |
|
Haemangiopericytoma (n = 3) Patient 1 Patient 2 Patient 3 |
SD SD PD |
5.9 12.8 3.2 |
Alive (7.9) Dead (16.2) Alive (3.4) |
|
Haemangioendothelioma (n = 2) Patient 1 Patient 2 |
PD SD |
1.8 29.3 |
Dead (3.0) Dead (29.3) |
|
Myxofibrosarcoma (n = 4 ) Patient 1 Patient 2 Patient 3 Patient 4 |
PD PD SD SD |
2.0 2.6 2.8 10.2 |
Alive (2.0) Dead (2.6) Alive (4.9) Dead (10.6) |
|
Spindle cell sarcoma (n = 3 ) Patient 1 Patient 2 Patient 3 |
SD PR PR |
5.7 5.0 3.6 |
LFU (5.7) Alive (5.0) Alive (3.7) |
|
MPNST (n = 4) Patient 1 Patient 2 Patient 3 Patient 4 |
PD SD PD NA |
4.6 9.9 1.0 1.1 |
Alive (31.6) Dead (12.8) LFU (17.7) Alive (1.1) |
|
Epithelioid sarcoma (n = 4) Patient 1 Patient 2 Patient 3 Patient 4 |
PR PR PR SD |
12.5 2.2 3.4 5.1 |
LFU (12.6) Alive (2.2) Alive (3.6) Alive (5.1) |
| Clear cell sarcoma (n = 1) | SD | 15.5 | Alive (15.5) |
|
UPS (n = 7) Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 |
SD PR PR NK SD SD SD |
11.2 5.2 4.1 1.3 17.3 8.9 5.3 |
Dead (18.8) Alive (5.2) Alive (4.1) Dead (1.3) Dead (17.5) LFU (8.9) Alive (5.3) |
| Retroperitoneal sarcoma (n = 1) | PD | 2.6 | Dead ( 4.3 ) |
| Angiosarcoma (n = 1) | PR | 5.8 | Alive (5.8) |
| Pleomorphic RMS (n = 1) | NA | 1.5 | Alive (1.5) |
PFS, Progression free survival; OS, Overall survival; ASPS, Alveolar soft part sarcoma; MPNST, Malignant peripheral nerve sheath tumour; UPS, Undifferentiated pleomorphic sarcoma; PR, Partial response; SD, Stable disease; PD, Progressive disease; NK, Not Known; NA, Not assessed; LFU, Lost to follow-up